AiCure

R&D Trends

Felicitex Therapeutics, Selvita collaborate to target cancer quiescence

Monday, November 10, 2014 12:18 PM

Cambridge, Mass.-based Felicitex Therapeutics, a privately owned drug discovery company, and Selvita, a Polish biotechnology company, have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors.

More... »


Study: CNS drugs have lower regulatory success rate, take longer to develop

Monday, November 10, 2014 12:02 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Developing drugs to treat a wide array of central nervous systems disorders—including depression, psychosis, epilepsy and Alzheimer’s disease—takes longer and has an overall success rate of less than half that of other types of drug candidates.

More... »

CenterWatch

BIND Therapeutics inks oncology agreement with Merck

Friday, November 7, 2014 01:25 PM

BIND Therapeutics, a Cambridge, Mass.-based clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has signed an R&D agreement with Merck, through a subsidiary, to discover and develop novel nanomedicines for oncology. This collaboration will leverage BIND's proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck's preclinical oncology portfolio.

More... »

Bill & Melinda Gates Foundation awards PATH $156M for malaria research

Friday, November 7, 2014 01:23 PM

The Bill & Melinda Gates Foundation, of Seattle, Wash., has awarded $156 million to PATH, a Seattle-based international nonprofit organization, to support the PATH Malaria Vaccine Initiative (MVI) in building new vaccines that will interrupt the cycle of malaria parasite transmission and help realize the "accelerating to zero" agenda. Such vaccines would ensure parasite reintroduction is prevented by providing what could be called an "immunological bed net."

More... »

Study: Medication nonadherence a barrier to long-term health and public safety

Friday, November 7, 2014 01:22 PM

One out of four samples collected from patients with serious mental illness (SMI) did not contain the prescribed antipsychotic medication, according to clinical research from Ameritox's Ingenuity Health, a Baltimore, Md.-based provider of monitoring solutions to behavioral health clinicians. Coupled with nearly 40% of samples testing positive for illicit drugs or non-prescribed medications, the study illustrates the pervasiveness of medication nonadherence among those with SMI and highlights the potential barriers to long-term health and public safety.

More... »

EFPIA, Innovative Medicines Initiative form $348.2M Ebola+ program

Friday, November 7, 2014 01:19 PM

European Federation of Pharmaceutical Industries and Associations (EFPIA), a representative of the pharmaceutical industry operating in Europe, its specialized group Vaccines Europe and the Innovative Medicines Initiative have launched a $348.2 million call for proposals for an Innovative Medicines Initiative (IMI) program aimed to address the current Ebola crisis. The Ebola+ program will bring together the pharma industry and researchers in a collaborative program aimed to cover the current outbreak, as well as future needs in the space of hemorrhagic fevers.

More... »

Study: Large enterprises view business transformation as essential

Thursday, November 6, 2014 12:41 PM

Continual business transformation is crucial for companies to stay ahead of emerging players and maintain a competitive edge. From bringing new offerings to market to deploying IT systems to major capital expenditures, business transformation can take countless forms. Many large institutions, however, are struggling with their transformation efforts, according to a study from Oracle, a multinational computer technology corporation headquartered in Redwood City, Calif., and Forbes.

More... »

AstraZeneca, Manchester University form Advanced Drug Delivery Center

Thursday, November 6, 2014 12:31 PM

The University of Manchester and AstraZeneca have entered into a strategic collaboration to develop cutting-edge technologies designed to enhance the way drugs work and deliver better health outcomes for patients. Together, they are launching the North West Center for Advanced Drug Delivery, which will be housed in Manchester Pharmacy School and will have links into a wide range of research groups throughout the university.

More... »

Proteostasis Therapeutics, Astellas form $1.2B collaboration

Wednesday, November 5, 2014 12:54 PM

Proteostasis Therapeutics, a Cambridge, Mass.-based company developing novel therapeutics to address diseases caused by defects in protein folding, trafficking and clearance, and Astellas Pharma have entered into a worldwide R&D collaboration for therapeutic candidates that modulate the unfolded protein response (UPR) through the use of Proteostasis Therapeutics’ proprietary Disease Relevant Translation (DRT) and Proteostasis Network platform.

More... »

Report: Biosimilars could create $44B in healthcare savings

Wednesday, November 5, 2014 12:52 PM

Introducing competing biosimilar versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the U.S. by $44 billion over the next decade, according to a new analysis from RAND, a Boston, Mass.-based nonprofit research organization that develops solutions to public policy challenges.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs